Lipid management in individuals with type 2 diabetes mellitus: Analysis of a hospital-based series

IF 1.9 4区医学 Q4 ENDOCRINOLOGY & METABOLISM

Endocrinologia Diabetes Y Nutricion Pub Date : 2026-03-01 Epub Date: 2026-03-07 DOI:10.1016/j.endien.2026.501674

João D. Martins, Débora Silveira, Henrique Pina, Inês Manique, Sílvia Guerra, Cristina Valadas

{"title":"Lipid management in individuals with type 2 diabetes mellitus: Analysis of a hospital-based series","authors":"João D. Martins, Débora Silveira, Henrique Pina, Inês Manique, Sílvia Guerra, Cristina Valadas","doi":"10.1016/j.endien.2026.501674","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and aims</h3><div>People with type 2 diabetes (T2DM) face higher cardiovascular risk, making lipid control essential. The European Society of Cardiology (ESC) updated its clinical practice guidelines in 2023, introducing the SCORE2-Diabetes risk calculator. This study evaluates lipid control, lipid-lowering therapy, and CV risk reclassification in full compliance with the 2021 and 2023 ESC clinical practice guidelines.</div></div><div><h3>Methods and results</h3><div>We analyzed T2DM patients (40–69 years) treated at our hospital Endocrinology-Diabetes outpatient clinic from January through October 2023. Hospital records and the Portuguese National Health System database were used to assess CV risk, LDL-c target achievement, risk classification changes, and lipid-lowering therapy, including statin potency. The study included a total of 214 individuals (mean age, 58.5 years; 61.2% men). Under the 2021 ESC clinical practice guidelines, a total of 38.3% patients were categorized as very high risk, 51.9% as high risk, and 9.8% as moderate risk, with LDL-c targets met in 22.0%, 29.7%, and 47.6%, respectively. Under the 2023 clinical practice guidelines, 43.0% were very high risk; 25.7%, high risk; 24.8%, moderate risk; and 6.5%, low risk, with LDL-c targets met in 21.7%, 29.1%, 54.7%, and 71.4%, respectively. Risk classification changed for 32.7% of patients. Regarding treatment, 23.83% were not on lipid-lowering therapy, while 26.17% used high-intensity statins.</div></div><div><h3>Conclusion</h3><div>Lipid control in T2DM remains suboptimal, especially in high-risk patients. While improvements are being made, tools such as the SCORE2-Diabetes may improve individualized treatment and reduce cardiovascular events.</div></div>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"73 3","pages":"Article 501674"},"PeriodicalIF":1.9000,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrinologia Diabetes Y Nutricion","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2530018026000119","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/7 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Background and aims

People with type 2 diabetes (T2DM) face higher cardiovascular risk, making lipid control essential. The European Society of Cardiology (ESC) updated its clinical practice guidelines in 2023, introducing the SCORE2-Diabetes risk calculator. This study evaluates lipid control, lipid-lowering therapy, and CV risk reclassification in full compliance with the 2021 and 2023 ESC clinical practice guidelines.

Methods and results

We analyzed T2DM patients (40–69 years) treated at our hospital Endocrinology-Diabetes outpatient clinic from January through October 2023. Hospital records and the Portuguese National Health System database were used to assess CV risk, LDL-c target achievement, risk classification changes, and lipid-lowering therapy, including statin potency. The study included a total of 214 individuals (mean age, 58.5 years; 61.2% men). Under the 2021 ESC clinical practice guidelines, a total of 38.3% patients were categorized as very high risk, 51.9% as high risk, and 9.8% as moderate risk, with LDL-c targets met in 22.0%, 29.7%, and 47.6%, respectively. Under the 2023 clinical practice guidelines, 43.0% were very high risk; 25.7%, high risk; 24.8%, moderate risk; and 6.5%, low risk, with LDL-c targets met in 21.7%, 29.1%, 54.7%, and 71.4%, respectively. Risk classification changed for 32.7% of patients. Regarding treatment, 23.83% were not on lipid-lowering therapy, while 26.17% used high-intensity statins.

Conclusion

Lipid control in T2DM remains suboptimal, especially in high-risk patients. While improvements are being made, tools such as the SCORE2-Diabetes may improve individualized treatment and reduce cardiovascular events.

查看原文本刊更多论文

2型糖尿病患者的脂质管理：基于医院系列的分析

背景和目的：2型糖尿病（T2DM）患者有较高的心血管风险，因此控制血脂至关重要。欧洲心脏病学会（ESC）于2023年更新了其临床实践指南，引入了score2 -糖尿病风险计算器。本研究完全按照2021年和2023年ESC临床实践指南评估血脂控制、降脂治疗和CV风险重新分类。方法和结果：我们分析了2023年1月至10月在我院内分泌-糖尿病门诊治疗的2型糖尿病患者（40-69岁）。使用医院记录和葡萄牙国家卫生系统数据库来评估CV风险、LDL-c目标实现情况、风险分类变化和降脂治疗，包括他汀类药物效力。该研究共纳入214人（平均年龄58.5岁，男性61.2%）。根据2021年ESC临床实践指南，共有38.3%的患者被归类为非常高风险，51.9%为高风险，9.8%为中度风险，分别有22.0%，29.7%和47.6%的患者达到LDL-c目标。根据2023年临床实践指南，43.0%为非常高风险；25.7%为高危人群；中度风险24.8%；低危组为6.5%，分别达到了21.7%、29.1%、54.7%和71.4%的LDL-c目标。32.7%的患者风险分级发生改变。在治疗方面，23.83%的患者未接受降脂治疗，26.17%的患者使用高强度他汀类药物。结论：T2DM患者的脂质控制仍然不够理想，特别是在高危患者中。在不断改进的同时，SCORE2-Diabetes等工具可能会改善个体化治疗并减少心血管事件。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Endocrinologia Diabetes Y Nutricion Multiple-

CiteScore

2.10

自引率

10.50%

发文量

期刊介绍： Endocrinología, Diabetes y Nutrición is the official journal of the Spanish Society of Endocrinology and Nutrition (Sociedad Española de Endocrinología y Nutrición, SEEN) and the Spanish Society of Diabetes (Sociedad Española de Diabetes, SED), and was founded in 1954. The aim of the journal is to improve knowledge and be a useful tool in practice for clinical and laboratory specialists, trainee physicians, researchers, and nurses interested in endocrinology, diabetes, nutrition and related disciplines. It is an international journal published in Spanish (print and online) and English (online), covering different fields of endocrinology and metabolism, including diabetes, obesity, and nutrition disorders, as well as the most relevant research produced mainly in Spanish language territories. The quality of the contents is ensured by a prestigious national and international board, and by a selected panel of specialists involved in a rigorous peer review. The result is that only manuscripts containing high quality research and with utmost interest for clinicians and professionals related in the field are published. The Journal publishes Original clinical and research articles, Reviews, Special articles, Clinical Guidelines, Position Statements from both societies and Letters to the editor. Endocrinología, Diabetes y Nutrición can be found at Science Citation Index Expanded, Medline/PubMed and SCOPUS.